Antihyperglycemic-dipeptidyl peptidase-4 (DPP-4) Inhibitors

Antihyperglycemic dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly referred to as gliptins, are an established class of oral medications used primarily to improve glycemic control in adults with type 2 diabetes mellitus These agents exert their therapeutic effect by selectively inhibiting the DPP-4 enzyme, which slows the rapid degradation of endogenous incretin hormones, including glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide Elevated active incretin concentrations...

Antihyperglycemic dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly referred to as gliptins, are an established class of oral medications used primarily to improve glycemic control in adults with type 2 diabetes mellitus Consequently, they serve as adjunctive therapy to diet and exercise, either as monotherapy or in combination with other antihyperglycemic drugs, without being indicated for type 1 diabetes or diabetic ketoacidosis

These agents exert their therapeutic effect by selectively inhibiting the DPP-4 enzyme, which slows the rapid degradation of endogenous incretin hormones, including glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide

Elevated active incretin concentrations stimulate glucose-dependent insulin secretion from pancreatic beta cells while suppressing inappropriate glucagon secretion from alpha cells, effectively lowering postprandial and fasting blood glucose levels